Assyro Team
15 min read
Good Distribution Practice (GDP): Pharmaceutical Supply Chain Compliance
Quick Answer
Good Distribution Practice (GDP) is the set of quality standards governing the wholesale distribution of medicinal products, ensuring that product quality is maintained throughout the supply chain from manufacturer to patient. The primary regulatory frameworks are EU GDP guidelines (2013/C 343/01), WHO TRS 957 Annex 5, and national regulations. GDP covers ten key areas: quality management, personnel, premises and equipment, documentation, operations, complaints and recalls, outsourced activities, self-inspections, transportation, and provisions specific to brokers. Compliance requires a Wholesale Distribution Authorisation (WDA) in the EU and adherence to state licensing requirements in the US.
Key Takeaways
Key Takeaways
- GDP covers ten key areas: quality management, personnel, premises/equipment, documentation, operations, complaints/recalls, outsourced activities, self-inspections, transportation, and broker provisions
- EU GDP compliance requires a Wholesale Distribution Authorisation (WDA); the US relies on state-level licensing requirements for pharmaceutical distributors
- Temperature-controlled distribution requires validated shipping systems, continuous temperature monitoring, and documented deviation management for excursions
- Counterfeit prevention is a core GDP requirement, implemented through supply chain verification (EU Falsified Medicines Directive serialization, US DSCSA track-and-trace)
- A drug product manufactured under perfect GMP conditions is worthless if it degrades during distribution. GDP bridges the quality gap between the factory gate and the patient. It ensures that the medicinal product reaching the pharmacy, hospital, or patient is the same quality as the product that left the manufacturer's warehouse.
- The pharmaceutical supply chain is long, complex, and vulnerable. Products may pass through multiple distributors, cross international borders, sit in customs warehouses, travel through extreme climates, and change hands several times before reaching the end user. At each point, product integrity can be compromised by temperature excursions, physical damage, theft, diversion, or counterfeiting.
- GDP provides the quality framework for every link in this chain. It is the distribution equivalent of GMP, and regulatory enforcement is increasing globally.
- In this guide, you'll learn:
- The EU GDP regulatory framework and its key requirements
- WHO GDP guidelines and their global applicability
- The ten key GDP requirement areas
- Supplier and customer qualification obligations
- Temperature-controlled distribution requirements
- Counterfeit prevention and supply chain security
- US distribution requirements and state-level regulations
- ---
Regulatory Framework
EU GDP Guidelines (2013/C 343/01)
The EU GDP guidelines, published on November 5, 2013, are the primary regulatory framework for pharmaceutical distribution in Europe. They replace the previous 1994 guidelines and incorporate significant enhancements in temperature control, risk management, and supply chain security.
Applicability: All entities involved in the wholesale distribution of medicinal products within the EU/EEA, including:
- Wholesale distributors
- Marketing authorisation holders (MAH) performing distribution activities
- Manufacturers performing distribution activities beyond their manufacturing license
- Third-party logistics (3PL) providers handling medicinal products
- Brokers (intermediaries who do not physically handle products)
Legal basis: Directive 2001/83/EC (as amended), specifically Articles 76-85b.
Key structural elements of EU GDP:
| Chapter | Topic | Summary |
|---|---|---|
| 1 | Quality Management | Quality system, Responsible Person, management review |
| 2 | Personnel | Training, hygiene, Responsible Person qualifications |
| 3 | Premises and Equipment | Warehouse design, temperature control, security |
| 4 | Documentation | SOPs, records, electronic systems |
| 5 | Operations | Receipt, storage, supply, export, returns, recalls |
| 6 | Complaints and Recalls | Complaint handling, product recall procedures |
| 7 | Outsourced Activities | Contract arrangements, quality agreements |
| 8 | Self-Inspection | Internal audit program |
| 9 | Transportation | Temperature control, vehicle qualification, monitoring |
| 10 | Specific Provisions for Brokers | Requirements for intermediaries without physical possession |
WHO TRS 957 Annex 5 (2010)
WHO's Good Distribution Practices for pharmaceutical products provides the global reference standard, particularly for countries without their own GDP regulations.
WHO GDP covers:
- Organization and management
- Personnel
- Quality management
- Premises, warehousing, and storage
- Vehicles and equipment
- Shipment containers and container labelling
- Dispatch and receipt
- Product recalls
- Rejected and returned products
- Counterfeit pharmaceutical products
- Importation
- Contract activities
- Self-inspections
US Regulatory Framework
The US does not have a single federal GDP guideline. Distribution is regulated through:
| Regulation/Law | Scope |
|---|---|
| FDA 21 CFR 211.142, 211.150 | Drug CGMP requirements for warehousing and distribution |
| Drug Supply Chain Security Act (DSCSA, 2013) | Product tracing, verification, and authorized trading partner requirements |
| State Board of Pharmacy regulations | Wholesale distributor licensing (varies by state) |
| USP <1079> | Informational chapter on good storage and distribution practices |
DSCSA milestones (as of 2026):
- Transaction documentation requirements: Active
- Product verification requirements: Active
- Electronic interoperable tracing (unit-level): Enhanced requirements phased in (FDA has granted stabilization periods for industry readiness)
- Authorized Trading Partner verification: Active
Key GDP Requirement Areas
1. Quality Management System
EU GDP Chapter 1 requirements:
| Element | Requirement |
|---|---|
| Quality system | Documented quality management system covering all distribution activities |
| Responsible Person (RP) | Designated person with defined qualifications and responsibilities |
| Management review | Periodic review of the quality system for effectiveness |
| Risk management | Risk-based approach to quality system processes |
| Change control | Documented change control for processes, premises, equipment |
| CAPA | System for corrective and preventive actions |
| Management accountability | Senior management responsibility for quality culture |
Responsible Person (RP):
The RP is the GDP equivalent of the Qualified Person (QP) in GMP. EU GDP Section 2.2 requires:
- Permanent and continuous availability during normal operating hours
- Qualifications: typically a degree in pharmacy or related science
- Responsibilities include ensuring GDP compliance, managing recalls, approving returns, and approving outsourced activities
2. Personnel
| Requirement | Details |
|---|---|
| Adequate staffing | Sufficient number of competent personnel for all distribution activities |
| Training program | Initial and ongoing GDP training for all personnel |
| Hygiene requirements | Standards for personal hygiene relevant to product handling |
| Key personnel identification | Defined roles for Responsible Person, warehouse manager, and key quality functions |
| Temporary staff | Must receive same training as permanent staff |
3. Premises and Equipment
Warehouse requirements:
| Requirement | Specification |
|---|---|
| Temperature control | Maintain storage conditions per product label requirements |
| Temperature mapping | Performed to identify temperature extremes within the warehouse |
| Temperature monitoring | Continuous monitoring at locations identified during mapping |
| Security | Physical security measures to prevent unauthorized access |
| Segregation | Separate areas for receiving, quarantine, storage, dispatch, returns, rejected goods |
| Pest control | Documented pest control program |
| Cleanliness | Regular cleaning and maintenance program |
| Lighting | Sufficient for accurate product identification and handling |
Equipment requirements:
- Calibrated monitoring equipment (temperature loggers, thermometers)
- Material handling equipment maintained in good condition
- IT systems validated for data integrity
4. Documentation
| Document Type | Examples |
|---|---|
| Standard Operating Procedures | Receipt, storage, dispatch, returns, recall, complaints, temperature excursion management |
| Records | Receipt records, dispatch records, temperature monitoring records, training records |
| Quality agreements | Agreements with outsourced service providers |
| Supplier and customer records | Qualification documentation, authorized status verification |
| Deviation records | Documentation of any departure from approved procedures |
Record retention: Per EU GDP, records must be retained for at least 5 years (or longer if required by national law).
5. Operations
Qualification of suppliers and customers:
This is a critical GDP requirement often overlooked. Before supplying or receiving medicinal products:
Supplier qualification:
| Verification | How |
|---|---|
| Wholesale Distribution Authorisation (WDA) | Check national WDA database |
| Manufacturing authorisation | Check EudraGMDP database for EU manufacturers |
| GDP compliance | Review audit reports, regulatory status |
| Product legitimacy | Verify product through supply chain documentation |
Customer qualification:
| Verification | How |
|---|---|
| Authorization to receive medicinal products | Verify pharmacy/hospital license or WDA |
| Legitimate business | Check registration, physical address, regulatory status |
| Controlled substance license | Additional verification for scheduled drugs |
Receipt of goods:
| Step | Requirement |
|---|---|
| Visual inspection | Check for damage, correct product, correct quantity |
| Temperature check | Review temperature monitoring data from shipment |
| Documentation check | Verify delivery note, batch numbers, expiry dates |
| Quarantine | Place received goods in quarantine until quality checks completed |
| Release | Release from quarantine only after QA approval |
Dispatch and supply:
| Requirement | Details |
|---|---|
| FIFO/FEFO | First Expired First Out is preferred; First In First Out as alternative |
| Correct picking and packing | Verified against order documentation |
| Appropriate packaging | Protective packaging per product requirements |
| Documentation | Delivery note with product, batch, quantity, supplier, customer information |
| Traceability | Full traceability from receipt to supply |
6. Complaints and Recalls
| Process | Requirement |
|---|---|
| Complaint handling | Written procedure for receiving, evaluating, and responding to complaints |
| Recall procedure | Documented recall procedure; ability to initiate recall at any time |
| Recall simulation | Periodic mock recalls to test effectiveness (EU GDP recommends annually) |
| Recall records | Complete records of all recall actions, including effectiveness assessment |
| Regulatory notification | Notify competent authority of any quality defect that may result in recall |
7. Outsourced Activities
When distribution activities are outsourced to third-party logistics (3PL) providers:
| Requirement | Details |
|---|---|
| Written contract | Quality agreement defining responsibilities |
| Audit program | Regular audits of 3PL provider GDP compliance |
| Competence assessment | Verify 3PL has necessary authorizations and capabilities |
| RP oversight | Responsible Person must have oversight of outsourced activities |
| Subcontracting | 3PL must obtain approval before subcontracting any activities |
8. Self-Inspection
| Element | Requirement |
|---|---|
| Self-inspection program | Regular internal audits covering all GDP requirements |
| Frequency | At least annually; risk-based scheduling for interim audits |
| Personnel | Conducted by trained, independent auditors |
| CAPA | Findings must be addressed with corrective and preventive actions |
| Records | Self-inspection reports retained per documentation requirements |
| Management review | Results included in management review of the quality system |
Temperature-Controlled Distribution
GDP Temperature Requirements
EU GDP Chapter 9 (Transportation) provides specific requirements:
| Requirement | Details |
|---|---|
| Risk assessment | Evaluate temperature risks for each distribution route and mode |
| Vehicle qualification | Temperature mapping of vehicles under representative conditions |
| Equipment maintenance | Temperature control equipment regularly maintained and calibrated |
| Monitoring | Temperature monitoring throughout transport; data reviewed upon receipt |
| Deviation management | Procedures for temperature excursion investigation and product disposition |
| Seasonal considerations | Assess and mitigate seasonal temperature risks |
Storage Condition Categories
| Category | Temperature Range | Examples |
|---|---|---|
| Do not store above 30C | Up to 30C | Many oral solid dosage forms |
| Do not store above 25C | Up to 25C | Some oral solids, topicals |
| Store at 2-8C | Refrigerated | Biologics, vaccines, insulins |
| Store below -20C | Frozen | Some biologics, cell therapies |
| Below -60C | Ultra-cold | mRNA vaccines, some gene therapies |
Transport Qualification
| Element | Requirement |
|---|---|
| Packaging qualification | Insulated packaging validated for required temperature range and duration |
| Route validation | Representative routes tested under seasonal extremes |
| Carrier qualification | Transport providers assessed for GDP compliance |
| Emergency procedures | Plans for vehicle breakdown, delayed delivery, extreme weather |
Counterfeit Prevention and Supply Chain Security
The Counterfeit Problem
WHO estimates that up to 10% of medicines globally are substandard or falsified. GDP plays a critical role in preventing counterfeit products from entering the legitimate supply chain.
EU Falsified Medicines Directive (FMD) - Directive 2011/62/EU
The FMD introduced mandatory safety features for medicinal products in the EU:
| Feature | Description |
|---|---|
| Unique identifier | 2D data matrix code on each pack (serialization) |
| Anti-tampering device | Tamper-evident seal on packaging |
| Verification | Pharmacies and wholesalers must verify authenticity before dispensing/supply |
| End-to-end verification | Manufacturer uploads serial numbers to EU hub; pharmacist/hospital decommissions at point of dispensing |
GDP Controls Against Counterfeiting
| Control | Description |
|---|---|
| Supplier qualification | Only source from authorized, verified suppliers |
| Product verification | Check serial numbers, tamper-evident features, visual appearance |
| Supply chain documentation | Maintain complete chain of custody records |
| Suspicious product procedure | Written procedure for handling suspected counterfeit products |
| Regulatory reporting | Report any suspected counterfeit to competent authority immediately |
| Secure storage | Physical security measures to prevent unauthorized access to inventory |
| Employee awareness | Training on recognizing counterfeit indicators |
US Drug Supply Chain Security Act (DSCSA)
| DSCSA Requirement | Status (2026) |
|---|---|
| Transaction information (TI) | Required for all transactions |
| Transaction history (TH) | Required for all transactions |
| Transaction statement (TS) | Required for all transactions |
| Product verification | Required upon request or suspicion |
| Electronic interoperable tracing | Phased implementation (FDA stabilization period extended) |
| Authorized trading partner verification | Required |
| Licensure verification | Required |
GDP Inspections
What Inspectors Assess
| Inspection Focus | What They Look For |
|---|---|
| Quality system | Documentation, SOPs, management review records |
| Responsible Person | Qualifications, availability, documented responsibilities |
| Premises | Temperature control, cleanliness, segregation, security |
| Temperature records | Continuous monitoring data, mapping studies, excursion investigations |
| Supplier/customer qualification | Verification records, authorized status checks |
| Traceability | Ability to trace product from receipt through dispatch |
| Recall capability | Mock recall results, recall procedures, communication plans |
| Returns handling | Segregation, assessment procedures, disposition records |
| Self-inspection | Program documentation, findings, CAPA follow-up |
| Complaints | Handling procedures, investigation records, trending |
Common GDP Inspection Findings
| Finding | Frequency | Prevention |
|---|---|---|
| Inadequate temperature monitoring or mapping | High | Comprehensive mapping and monitoring program |
| Incomplete supplier or customer qualification | High | Systematic qualification program with periodic re-evaluation |
| SOPs not followed or not current | High | Regular SOP review cycle; training verification |
| Inadequate returns handling | Medium | Written procedure with clear assessment criteria |
| Responsible Person not adequately fulfilling role | Medium | Defined RP responsibilities, adequate time allocation |
| Incomplete traceability records | Medium | End-to-end documentation from receipt to dispatch |
| No mock recall conducted | Medium | Annual mock recall exercise with documented results |
| Temperature excursions not investigated | High | Written excursion management procedure with disposition criteria |
Regulatory References
| Reference | Title | Relevance |
|---|---|---|
| EU GDP (2013/C 343/01) | Guidelines on Good Distribution Practice of Medicinal Products for Human Use | Primary EU GDP guideline |
| Directive 2001/83/EC | Community Code Relating to Medicinal Products for Human Use | Legal basis for EU GDP requirements |
| Directive 2011/62/EU | Falsified Medicines Directive | Anti-counterfeiting requirements |
| EU Delegated Regulation 2016/161 | Safety Features on Medicinal Products | Serialization and verification requirements |
| WHO TRS 957 Annex 5 (2010) | Good Distribution Practices for Pharmaceutical Products | WHO global GDP standard |
| WHO TRS 961 Annex 9 (2011) | Storage and Transport of Temperature-Sensitive Pharmaceutical Products | Temperature control guidance |
| 21 CFR 211.142 | Warehousing Procedures | US CGMP warehousing requirements |
| 21 CFR 211.150 | Distribution Procedures | US CGMP distribution requirements |
| Drug Supply Chain Security Act (2013) | Title II of the Drug Quality and Security Act | US supply chain tracing requirements |
| USP <1079> | Good Storage and Distribution Practices for Drug Products | US pharmacopeial guidance |
| PIC/S PI 021-1 (2014) | Good Distribution Practice for Pharmaceutical Products | PIC/S GDP inspection guidance |